Fusion proteins for prodrug activation

US7273727B2 · kind B2 · utility

Assignee

• Behringwerke Aktiengesellschaft · DE

Inventors

• Mathias Gehrmann · Tönisvorst, DE
• Gerhard Seeman · Lollar, DE
• Klaus Bosslet · Marburg, DE
• Jorg Czech · Marburg, DE

Key dates

• Filing date: May 23, 2005
• Grant date: Sep 25, 2007
• Expiry date: Aug 19, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is composed of a single polypeptide chain. It is advantageous for covalently bonded carbohydrates to be present on the polypeptide chain.